Key result
Intravenous application of mesenchymal stromal cells in mice with CVB3-induced acute myocarditis significantly reduced myocardial expression of proinflammatory cytokines and improved maximal left ventricular pressure by 64% compared to PBS.
Why the study?
Does intravenous application of human mesenchymal stromal cells improve left ventricular dysfunction and reduce myocardial inflammation in mice with CVB3-induced acute myocarditis?
Does intravenous application of human mesenchymal stromal cells improve left ventricular dysfunction and reduce myocardial inflammation in mice with CVB3-induced acute myocarditis?
Effect estimate: 64% higher
p-value: p=<0.0001
Systemic application of mesenchymal stromal cells, but not cardiac fibroblasts, exerts beneficial immunomodulatory effects and ameliorates cardiac dysfunction in experimental viral myocarditis.
No takes yet. Share an insight, caveat, or question.
Supports MSC immunomodulation in murine viral myocarditis; leaves open human translation and clinical trials.
Savvatis et al. (2012) studied CVB3-induced acute myocarditis (n=60). Human mesenchymal stromal cells (MSCs) vs. PBS or human cardiac fibroblasts was evaluated on Maximal left ventricular pressure (LVPmax) (64% higher, p=<0.0001). Intravenous application of mesenchymal stromal cells in mice with CVB3-induced acute myocarditis significantly reduced myocardial expression of proinflammatory cytokines and improved maximal left ventricular pressure by 64% compared to PBS.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: